

## **FOR IMMEDIATE RELEASE**

---

For more information, contact:

**Kevin M. Smith**  
President & CEO  
CID4  
[kevin.smith@cid4.com](mailto:kevin.smith@cid4.com)  
(720) 859-4043

### **Colorado Institute for Drug, Device and Diagnostic Development Awards Funding to Flashback Technologies**

*The Colorado Institute for Drug, Device and Diagnostic Development (CID4) has selected Longmont, CO-based Flashback Technologies, Inc. to receive funding and management assistance.*

**Aurora, CO August 1, 2011** – The Colorado Institute for Drug, Device and Diagnostic Development (CID4), a 501(c)(3) not-for-profit entity focused on advancing the Colorado life science ecosystem through company creation and job growth, has selected Longmont, Colorado-based Flashback Technologies, Inc. to receive funding and management assistance. Flashback is advancing development of their proprietary learning framework for the real-time analysis of physiological data.

Hemorrhage is the number one cause of potentially preventable death on the battlefield and in civilian trauma settings. Work under development includes a device powered by software that quickly and reliably detects and estimates blood loss volume and predicts a time to cardiovascular collapse.

Discoveries at the University of Colorado, Anschutz Medical Campus, Department of Surgery, the University of Colorado, Boulder, Department of Computer Science, and the U.S. Army Institute of Surgical Research have revealed several previously unknown hemodynamic relationships leading to a patent-pending platform technology for the real-time analysis of human vital sign data. A set of algorithms, collectively termed the Cardiovascular Reserve Monitor (CRM), is under development with funding from the U.S. Army. The CRM takes as inputs non-invasive physiological sensor data that in real-time: 1) Detects the early onset of hypovolemia (blood loss) 2) Estimates blood loss volume, and 3) Predicts a patient's individual risk for cardiovascular collapse.

Early intervention is associated with reduced morbidity and mortality. The CRM predicts the point at which an individual will experience hemodynamic decompensation (onset of shock) well in advance of changes in standard vital signs. Flashback's CRM is directed at improving clinical outcomes for trauma patients with unrecognized hemorrhage, as well as other forms of volume loss.

## **FOR IMMEDIATE RELEASE**

---

“The work currently being done by Flashback has the potential to revolutionize patient care in emergency settings by giving healthcare professionals previously unavailable real-time information,” said Kevin M. Smith, President and CEO of CID4. “We are pleased to be able to assist in the development of this important technology which we expect will eventually migrate beyond emergency medicine,” continued Smith, who will serve on the Flashback Board.

“We are very enthusiastic about receiving funding from CID4 and having access to their considerable management expertise,” said Greg Grudic, President and CEO of Flashback Technologies. “We have worked with CID4 on a variety of issues for several months and find their guidance to be a great asset to our progress in developing the Company.”

### **About Flashback Technologies**

Longmont, CO-based Flashback Technologies, Inc. is focused on advancing development of its Cardiovascular Reserve Monitor proprietary learning framework for the real-time analysis of physiological data. The Cardiovascular Reserve Monitor is directed at improving clinical outcomes for trauma patients with unrecognized hemorrhage, as well as other forms of volume loss. For more information visit <http://www.flashbacktechnologies.com>.

### **About the Colorado Institute for Drug, Device and Diagnostic Development**

Founded in 2009, the Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)(3) not-for-profit charitable organization whose mission is to advance the Colorado bioscience ecosystem through company creation and job growth. Active business management and capital work in tandem to help bridge the gap between discovery and product development. CID4 works to identify, fund and actively manage emerging life science technologies. This aim is achieved via an ongoing technology solicitation process augmented by additional deal flow sourcing through networked relationships. Active due diligence is provided by CID4 management in consultation with members of the CID4 Technical and Business Advisory Committee. For more information visit <http://CID4.com>.

###